Roche Specialty Market Focus Provides Refuge In “Unstable Environment”

Roche's return to prominence in the primary care market will wait until at least 2006, the company indicated during a July 24 analyst meeting in Zurich

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet